de web@aimee.ro | nov. 29, 2019 | Fără categorie
BUCHAREST, SEPTEMBER 15TH, 2015 – THE ROMANIAN ASSOCIATION OF GENERIC DRUG MANUFACTURERS (APMGR), representing generic drug manufacturing companies from Romania, demands that authorities withdraw abusive fiscal policies existing in the pharmaceutical field, in... de web@aimee.ro | nov. 29, 2019 | Fără categorie
THE CLAWBACK TAX ON Q1 2014 CONTINUES TO BE UNREASONABLY HIGH, AS THE PERCENTAGE „P” IN THE CALCULATION OF THE CLAWBACK IS OVER 20% OF THE SALE OF REIMBURSED MEDICINES APMGR REQUIRES THE NATIONAL HEALTH INSURANCE HOUSE (NHIH) TO BE MORE TRANSPARENT IN THE... de web@aimee.ro | nov. 29, 2019 | Fără categorie
BRUSSELS, 9 OCTOBER 2013 – On Tuesday 8th October, the European Generic medicines Association (EGA) launched its industrial policy vision for the future of the generic and biosimilar medicine industries in Europe at the EGA Industrial Policy Conference gathering... de web@aimee.ro | nov. 29, 2019 | Fără categorie
BRUSSELS, 1 July 2013 – The EGA welcomes the European Medicines Agency’s recommendation to the European Commission to approve the first two infliximab biosimilar products, both referenced to Remicade©. “This is a key milestone in the history of medicines in the... de web@aimee.ro | nov. 29, 2019 | Fără categorie
ATHENS, 13 June 2013 – Addressing delegates at the 19th EGA Annual Conference in Athens, Gudbjorg Edda Eggertsdottir stressed that generic and biosimilar medicines companies ensuring high-quality manufacturing jobs and know-how should remain in Europe;... de web@aimee.ro | nov. 29, 2019 | Fără categorie
Generic medicine producers that do not benefit from the introduction of new molecules on the list, would be severely affected by an unfair tax burden, with serious consequences for patient access to affordable treatment. The strict criteria introduced by the Ministry...